NCT00424034已完成1 期
Phase I Study of Ambrisentan - Single Dose Study in Healthy Japanese Male Subjects
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 主要终点
- Adverse events Change in Clinical laboratory test Vital sign 12-lead ECG Plasma concentration Urine concentration
研究概览
简要总结
To investigate the safety, tolerability, pharmacokinetics and the effect of food on pharmacokinetics after single oral administrations of GSK1325760A
详细描述
Phase1 study of GSK1325760A
- A double blind, single center, randomised, placebo-controlled, partially crossover, single dose study to investigate the safety, tolerability, pharmacokinetics and to assess the effect of food on pharmacokinetics of ascending oral doses of GSK1325760A in healthy Japanese male subject -
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 20 Years 至 64 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •They are considered as healthy by the investigator at screening. Healthy subjects are defined as individuals who are free from clinically significant illness or disease as determined by their medical history, physical examination, clinical laboratory tests, vital sign, 12-lead ECG, immunology tests and urinary drug screening tests.
- •They are Japanese males.
- •Aged 20 to 64 years, inclusive.
- •They have a body mass index (weight/height2) at screening in the range of 18.5 and <25.0 kg/m2 inclusive. Standard weight is in the range of 55-85 kg inclusive.
- •Blood pressure and pulse rate at screening within the normal range (systolic 90-140 mmHg, diastolic 40-90 mmHg, pulse rate 40-90bpm).
- •They have the following clinical laboratory test
- •Biochemistry (AST(GOT), ALT(GPT), ALP, LDH and gamma-GTP : within normal range at screening.
- •Haematology (RBC, Hb and Ht) below upper limit normal range at screening.
- •Normal ECG at screening (QTc value of <440msec).
- •They give their consent to be able to abstain from sexual intercourse or use condom for contraception from at screening until post-study screen.
- •They are capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.
- •They are non-smokers (at least 6 months).
- •They are able to attend all visits and complete the study.
排除标准
- •The subject has any clinically relevant abnormality on medical examination, vital sign, clinical laboratory test or medical history at screening in the medical opinion of the investigator or the subject has a medical history that is not considered as eligible for inclusion in this study by the investigator.
- •The subject has an allergy for any drug or idiosyncrasy. This excludes a pollen allergy without current symptoms.
- •The subject has participated in a clinical study or post-marketing study with an investigational or a non-investigational product or device during the previous 4 months of the first dosing.
- •The subject is concurrently participating in another clinical study or post-marketing study in which the subject is or will be exposed to an investigational or a non-investigational product or device.
- •The subject is positive for syphilis, HBs antigen, HCV antibody, HIV antibody, HTLV-1 antibody.
- •The subject is positive for urine drugs of abuse test.
- •The subject has donated a unit of blood (>400mL) within the previous 4 months or (>200mL) within the previous 1 month of screening.
- •The subject is currently taking regular (or a course of) medication (including prescribed drug, over-the-counter medication and herbal preparations). Medication nor permitted during the study must be discontinued 14 days prior to dosing.
- •The subject has a history or current conditions of drug abuse or alcoholism according to ICD
- •The subject has a history of regular alcohol consumption exceeding 7 drinks/week (1 drink = 350mL of beer) within 6 months of the first dosing.
结局指标
主要结局
Adverse events Change in Clinical laboratory test Vital sign 12-lead ECG Plasma concentration Urine concentration
时间窗: on 5 or 6 days after dosing
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
A Study to Determine the Effect of Food on the Pharmacokinetics of Abiraterone Acetate in Healthy Male PatientsHealthy VolunteersNCT01798628Cougar Biotechnology, Inc.36
已完成
1 期
Impact of Food on Pharmacokinetics and Pharmacodynamics of Asasantin ER in Healthy SubjectsHealthyNCT02273492Boehringer Ingelheim28
已完成
1 期
A Food Effect Study of TAK-385 Final FormulationJapanese Premenopausal Healthy Adult WomenNCT02792062Takeda12
已完成
1 期
Study to Investigate the Effect of Food on the Pharmacokinetics/Pharmacodynamics and Safety of CKD-519(CKD-519 FDI)DyslipidemiaNCT02484482Chong Kun Dang Pharmaceutical45
Unknown
1 期
Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187OverweightDiabetes Mellitus Type 2 in ObeseNCT01874366Piramal Enterprises Limited96